Aldeyra Therapeutics, Inc.’s ALDX share price has surged by 23.94%, which has investors questioning if this is right time to sell.

The following recap contains spoilers from the April 3 episode of CBS’ Matlock. With four episodes left to air (over the next ...

Aldeyra Therapeutics, Inc.’s ALDX share price has dipped by 76.92%, which has investors questioning if this is right time to ...

Compound Semiconductor™ is an Angel Business Communications publication.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

Discover growth opportunities with Edgewise Therapeutics, Inc. in the hypertrophic cardiomyopathy market. Click for my EWTX ...

Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.